Manja Boerman To Join Syngene Board as Independent Director

The Board of Directors of Syngene International Limited has approved the appointment of Manja Boerman as an Additional Director (Independent, Non-Executive) with effect from the date of allotment of Director Identification Number (DIN) until the Annual General Meeting to be held in the year 2027. Subject to the approval of the shareholders. The company shall inform the stock exchanges once the DIN has been allotted.

Manja Boerman is a distinguished leader in the biopharmaceutical industry with over 20 years of experience. Boerman’s career highlights include her tenure as President of Catalent Protein, Cell, and Gene Therapy at Aesica Pharmaceuticals, Patheon Biologics, and DSM Biologics, as well as her leadership as CEO of Kiadis Pharma and Regenesance. She is currently the CEO of Prothya Biosolutions (a blood plasma product company). She holds a PhD in biochemistry from the State University of New York, reflecting her strong academic background in life sciences. She began her career at DSM, where she held various positions in business development, licensing, and technology within DSM Biologics. She has been recognised for her expertise in clinical operations, strategic planning, and business development. She has contributed to numerous scientific publications and has been a prominent speaker at industry conferences.